SEGMENT REPORTING (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Segment Reporting Information, by Segment

The following table presents a summary of the revenues and Adjusted EBITDA of our two operating segments for the years ended December 31, 2024, 2023, and 2022:


	Year Ended December 31,
(In thousands)	2024		2023		2022
Revenues:
Financial Health	$	217,672	$	192,325	$	179,870
Patient Care	124,974		143,630		146,778
Total consolidated revenues	342,646		335,955		326,648

Less:
Financial Health expenses:
Cost of sales (excluding depreciation and amortization and stock compensation expense)	$	116,494	$	108,498	$	96,793
Product development	8,197		9,362		6,609
Sales and marketing	17,138		17,261		13,752
General and administrative expenses	39,680		34,008		27,497
Total Financial Health expenses	$	181,509	$	169,129	$	144,651
Patient Care expenses:
Cost of sales (excluding depreciation and amortization and stock compensation expense)	$	51,316	$	65,116	$	68,939
Product development	25,352		27,878		25,290
Sales and marketing	9,223		10,795		13,379
General and administrative expenses	18,676		18,941		18,490
Total Patient Care expenses	$	104,567	$	122,730	$	126,098
Total segment expenses	$	286,076	$	291,859	$	270,749

Adjusted EBITDA by Segment:
Financial Health	36,163		23,196		35,219
Patient Care	20,407		20,900		20,680
Total Adjusted EBITDA	$	56,570	$	44,096	$	55,899

Schedule of Reconciliation of Net Income from Continuing Operations to Adjusted Income (Loss) from Before Interest, Taxes, Depreciation and Amortization

The following table reconciles net income to adjusted EBITDA:


	Year Ended December 31,
(In thousands)	2024		2023		2022
Net income (loss), as reported	$	(20,439)	$	(48,434)	$	15,867
Deferred revenue and other acquisition-related adjustments	—		—		109
Depreciation expense	1,346		1,946		2,443
Amortization of software development costs	15,122		8,096		3,484
Amortization of acquisition-related intangibles	12,505		16,426		17,403
Stock-based compensation	5,520		3,271		5,173
Severance and other non-recurring charges	15,442		22,186		4,504
Interest expense and other, net	15,517		11,659		5,267
Impairment of goodwill	—		35,913		—
Impairment of trademark intangibles	—		2,342		—
Gain on contingent consideration	(1,044)		—		(565)
Loss on disposal of property and equipment	3,895		117		—
Gain on sale of AHT	(1,529)		—		—
Provision (benefit) for income taxes	10,235		(9,426)		2,214
Total adjusted EBITDA	$	56,570	$	44,096	$	55,899